Analysts Offer Insights on Healthcare Companies: Addus Homecare (ADUS) and United Therapeutics (UTHR)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Addus Homecare (ADUS – Research Report) and United Therapeutics (UTHR – Research Report) with bullish sentiments.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Addus Homecare (ADUS)
In a report released today, Ryan Langston from TD Cowen reiterated a Buy rating on Addus Homecare, with a price target of $140.00. The company’s shares closed last Wednesday at $107.60.
According to TipRanks.com, Langston has 0 stars on 0-5 stars ranking scale with an average return of
Currently, the analyst consensus on Addus Homecare is a Strong Buy with an average price target of $136.00, which is a 29.1% upside from current levels. In a report released yesterday, TipRanks – xAI also upgraded the stock to Buy with a $135.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
United Therapeutics (UTHR)
TD Cowen analyst Joseph Thome maintained a Buy rating on United Therapeutics today and set a price target of $575.00. The company’s shares closed last Wednesday at $535.10.
According to TipRanks.com, Thome is a 5-star analyst with an average return of
United Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $545.86, representing a 13.7% upside. In a report issued on February 17, UBS also maintained a Buy rating on the stock with a $645.00 price target.
